AbbVie Inc.
CARBIDOPA PRODRUGS
Last updated:
Abstract:
The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
Status:
Application
Type:
Utility
Filling date:
4 May 2020
Issue date:
20 Aug 2020